Research programme: bi-specific antibody therapeutics - Zymeworks/Merck & Co

Drug Profile

Research programme: bi-specific antibody therapeutics - Zymeworks/Merck & Co

Alternative Names: Azymetric scaffold; EFECT™

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zymeworks
  • Developer Merck & Co; Zymeworks
  • Class Bispecific antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 14 Nov 2017 Preclinical development in Autoimmune disorders and Cancer is ongoing in Canada
  • 09 Nov 2017 Merck plans preclinical trials for a bispecific antibody candidate developed in collaboration with Zymeworks
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top